Abraxis BioScience Shares Up 30% After Lung Cancer Drug Met Goals In Late-Stage Study (ABII)
Wednesday, March 17, 2010 - 11:02
Written on Wed, 03/17/2010 - 11:02am
By Chip Brian

3/17/2010- Abraxis BioScience (NASDAQ:ABII) shares rose 30% to $51.84 after the company said its Abraxane drug met its goals in a late-stage lung cancer study.
The company said that Abraxane with Taxol, in combination with chemotherapy, improved the overall response rate of patients in the study.
Abraxis expects to ask for FDA approval as a lung cancer treatment in 2011.

Keywords: abraxis bioscience

Ticker(s): ABII

Contact Chip Brian



Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.